Peripheral

Ventyx Biosciences Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Progress

Retrieved on: 
星期四, 五月 9, 2024
Volunteering, FDA, Modulation, Ulcerative colitis, Solipsism syndrome, CDAI, Food, Risk, Molina Healthcare, NLRP3, Research and development, CAPS, Plasma, Webcast, Science, Administration, TYK2, IBD, Obesity, Week, SAD, European Medicines Agency, Patient, Treatment, Peripheral, EMA, Inflammation, CSF, Cardiovascular disease, Biomarker, MACE, G&A, SAN, UC, Pharmaceutical industry

SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced financial results for the first quarter ended March 31, 2024, and highlighted recent pipeline and business progress.

Key Points: 
  • ET to discuss its first quarter 2024 financial results and provide a corporate update.
  • First Quarter 2024 Financial Results:
    Cash Position: Cash, cash equivalents and marketable securities were $302.6 million as of March 31, 2024.
  • Research and Development (R&D) expenses: R&D expenses were $33.7 million for the first quarter of 2024, compared to $35.4 million for the first quarter of 2023.
  • Net loss: Net loss was $38.6 million for the first quarter of 2024, compared to $38.9 million for the first quarter of 2023.

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results

Retrieved on: 
星期一, 五月 6, 2024
FDA, Total, ITK, Research, PTCL, PR, Doctor of Philosophy, Webcast, Fungal infection, Atopic dermatitis, RCC, Lymphoma, Vanderbilt University Medical Center, Lung cancer, Conference call, Kidney cancer, Conference, CRS, Peripheral, Assistant, PRS, NSCLC, Patient, Safety, Pembrolizumab, Modified, CTCL, Time management, Clinical trial, Division, Sale, A2A, Adenosine, HNSCC, T-cell lymphoma, Nivolumab, Ipilimumab, B-cell lymphoma, Disease, ALCL, Physician, Head, PTCL-NOS, Pharmaceutical industry

BURLINGAME, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the first quarter ended March 31, 2024.

Key Points: 
  • ET / 1:30 p.m. PT
    BURLINGAME, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the first quarter ended March 31, 2024.
  • Corvus anticipates initiating a registrational Phase 3 clinical trial of soquelitinib in patients with relapsed PTCL in the third quarter of 2024.
  • Corvus will host a conference call and webcast today, Monday, May 6, 2024, at 4:30 p.m.
  • ET (1:30 p.m. PT), during which time management will provide a business update and discuss the first quarter 2024 financial results.

Grand Opening of the April 2024 Global Sources Consumer Electronics and Electronic Components Shows

Retrieved on: 
星期四, 四月 11, 2024
Peripheral, Mouse, Global Sources, Sport, Communication, Esports Arena, Transport, Semiconductor, Carbon footprint, OMG, Growth, Business, DDT, ESG, Showgirls, Social responsibility, LPL, Video game

HONG KONG, April 11, 2024 /PRNewswire/ -- The highly anticipated April 2024 Global Sources Hong Kong Shows open today, marking a pivotal moment for the global procurement industry. As a premier online-to-offline (O2O) sourcing event, the first segment of the three-phase event, which runs from April 11 to 14, brings together two major professional shows of consumer electronics and electronic components, and kicks off with an impressive array of exhibitions showcasing innovative and cutting-edge technology products in esports and gaming hardware peripherals, outdoor electronics, computer peripherals, automotive electronics, audio-visual, commercial electronics, and electronic components. The shows feature around 150,000 products showcased across 4,000 booths from over 2,000 high-quality suppliers, including more than 200 original brand manufacturers.

Key Points: 
  • HONG KONG, April 11, 2024 /PRNewswire/ -- The highly anticipated April 2024 Global Sources Hong Kong Shows open today, marking a pivotal moment for the global procurement industry.
  • The Global Sources Hong Kong Shows have always been committed to providing a unique O2O service experience.
  • This year, Global Sources is debuting a new "Show Genie" feature within its mobile app, which includes e-badges, interactive maps, and the option to add exhibitor notes.
  • The onsite Global Sources Summit sessions during the first phase of the show focus on insightful discussions around cutting-edge topics in the consumer electronics industry.

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
星期二, 三月 19, 2024
Atopic dermatitis, Head, T helper cell, HNSCC, Patient, PTCL, Lung cancer, Ipilimumab, Asthma, CTCL, ALCL, Fungal infection, Pulmonary fibrosis, Lymphocyte, RCC, Clinical trial, CRS, Marketing, B-cell lymphoma, Research, PR, PTCL-NOS, Psoriasis, T-cell lymphoma, ASH, Webcast, Immunomodulation, Pembrolizumab, PRS, Exposition, Cancer, Nivolumab, Safety, Scleroderma, Food, NSCLC, Teva Pharmaceuticals, Modified, Lymphoma, Knowledge, Allergy, Immunodeficiency, Time management, Peripheral, Poster, FDA, ITK, Conference call, Kidney cancer, T helper 17 cell, Society, Preprint, BioRxiv, Autoimmunity, Physician, Total, Pharmaceutical industry

BURLINGAME, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2023.

Key Points: 
  • ET / 1:30 p.m. PT
    BURLINGAME, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2023.
  • We have several exciting opportunities in immunology, including plans for a randomized, placebo controlled clinical trial of soquelitinib in atopic dermatitis.
  • Mr. Arcara previously served as senior vice president, head global marketing & portfolio and strategy for the innovative medicines and biosimilars business at Teva Pharmaceuticals.
  • ET (1:30 p.m. PT), during which time management will provide a business update and discuss the fourth quarter and full year 2023 financial results.

Research Team Progresses to Final Phase in NIH Competition, Pioneering Autonomic Neuromodulation to Expand Applications for Spinal Stimulation

Retrieved on: 
星期四, 三月 21, 2024
Kessler Institute for Rehabilitation, Research, Blood pressure, Reward, Health, TIM, Applied Physics Laboratory, Reynolds Center, Johns Hopkins, SPARC, Learning, Caregiver, News, Rehabilitation, University, Doctor of Philosophy, MD, Quality of life, NIH, Peripheral, Kessler Foundation, Competition, Tetraplegia, Autonomic nervous system, Mobility, Safety, University of Louisville, Neurostimulation, Self-management, Dysautonomia, Bangladesh Technical Education Board, Select Medical, Common Fund for Commodities, Pharmaceutical industry

EAST HANOVER, N.J., March 21, 2024 /PRNewswire/ -- Marking significant progress towards improving the lives of individuals with spinal cord injuries, Kessler Foundation, University of Louisville, and John Hopkins Applied Physics Laboratory (with the support of Medtronic) have collaboratively won the $1,000,000 prize for Phase 2 of the Neuromod Prize for their project titled, "Neuromodulation of the lumbosacral spinal cord for improvement of autonomic function after spinal cord injury." With this win, the team advances to compete for the Phase 3 prize pool of $5 million.

Key Points: 
  • With this win, the team advances to compete for the Phase 3 prize pool of $5 million.
  • Phase 1 called for innovative therapy concepts and development plans, leading to Phase 2's proof-of-concept studies by the eight selected teams.
  • On February 27, 2024, the NIH announced the four Phase 2 victors, marking a breakthrough moment in neuromodulation research.
  • "Most importantly, what we are learning and sharing about neuromodulation through this Competition will influence new approaches to treating other types of disabling autonomic dysfunction."

Global Sources Hong Kong Shows inset for April 2024, with Gaming Products, Smart Home Appliances, and Sports & Outdoor Products Categories to Watch

Retrieved on: 
星期一, 三月 11, 2024
Health, EV, Culture, Growth, Sport, ESG, Peripheral, Electronics, Mouse, Sports equipment, DDT, Nature, OMG, Carbon, Global Sources, Ecosystem, Friendly, Showgirl, Crossroads International, Video game

HONG KONG, March 11, 2024 /PRNewswire/ -- Global Sources announced today that the Global Sources Hong Kong shows will take place at the AsiaWorld-Expo in Hong Kong from 11 to 30 April, 2024, catering to the demands of the global sourcing industry.

Key Points: 
  • HONG KONG, March 11, 2024 /PRNewswire/ -- Global Sources announced today that the Global Sources Hong Kong shows will take place at the AsiaWorld-Expo in Hong Kong from 11 to 30 April, 2024, catering to the demands of the global sourcing industry.
  • The show is expected to draw more than 100,000 professional buyers from various parts of the globe.
  • This showcase presents a variety of electronic components, semi-finished batteries, power supply equipment, connectors, and product application solutions.
  • It also integrates a wide array of upstream products from the semiconductor sector to establish a complete ecosystem within the electronics industry.

Ventyx Biosciences Reports Clinical Data for its NLRP3 Inhibitor Portfolio and Provides Pipeline Updates at Virtual Investor Event

Retrieved on: 
星期一, 三月 11, 2024
SAN, Ulcerative colitis, Week, CDAI, IC50, Solipsism syndrome, Peripheral, Obesity, Cerebrospinal fluid, Cardiovascular disease, Treatment, MACE, NLRP3, Volunteering, Inflammation, Modulation, QD, Safety, Biomarker, UC, CAPS, Pharmacokinetics, Webcast, Patient, Molina Healthcare, TYK2, CSF, PIPE, Plasma, FCAS, Risk, Pharmaceutical industry

SAN DIEGO, March 11, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, will provide clinical and pipeline updates today during its virtual investor event.

Key Points: 
  • We believe these data support the potential for VTX3232 to emerge as a best-in-class CNS-penetrant NLRP3 inhibitor for the treatment of neuroinflammatory diseases.
  • We believe these data establish compelling clinical proof of concept for our peripheral NLRP3 inhibitor VTX2735.
  • At our virtual investor event, we will present data from the ongoing Phase 2 open-label extension.
  • Ventyx will host a virtual investor event today, Monday, March 11, 2024 from 11:00AM to 12:30PM ET.

Cyber Acoustics Revolutionizes the Training of Call Center Agents

Retrieved on: 
星期二, 三月 5, 2024
QD, Environment, DECT, Noise, Acoustics, Peripheral, School, Bluetooth, Microsoft, ENC, Video game

In addition, the HS-1500BT allows coaches the freedom to move about the call center floor while maintaining a simultaneous secure wireless connection to their computer or tablet.

Key Points: 
  • In addition, the HS-1500BT allows coaches the freedom to move about the call center floor while maintaining a simultaneous secure wireless connection to their computer or tablet.
  • In addition, one HS-1500BT wireless headset can be shared with any number of agents, making it a cost-effective solution for contact centers.
  • This process can be repeated with any number of agent’s AC-204TR headsets that have been pre-paired to the coach’s HS-1500BT.
  • “The AC-204TR offers a way for BPOs to improve agent training by making it easier for coaches to connect to agent’s calls and offer guidance directly.

Cyber Acoustics Announces New Headset that Completely Eliminates Background Noise in Call Centers, Offices, Homes, and Hybrid Work Environments

Retrieved on: 
星期二, 三月 5, 2024
Avaya, Google Meet, Microsoft Windows, Outsourcing, RingCentral, Friends, BPO, Dog, Noise, Airport, Peripheral, GoTo Meeting, AHT, Human, Acoustics, Skype, School, City centre, Coffee, Family, Cisco Webex, Chromebook, Genesys, Zoom, Face, Software, Microsoft Teams, ENC, Electric motor

Call center success relies on a number of factors, with Average Handle Time (AHT) being one of the biggest.

Key Points: 
  • Call center success relies on a number of factors, with Average Handle Time (AHT) being one of the biggest.
  • The superior AI Noise Reduction in the AC-304 headset eliminates all background noise from an agent’s environment, and can lead to shorter call times and an improved AHT metric.
  • The noise-cancelation in the AC-304 is so effective, it eliminates background noise in even the loudest call center or office, no additional software required.
  • “Cyber Acoustics really aims to serve as a technology partner to our customers, not just a vendor,” said Steve Erickson, COO at Cyber Acoustics.

Ventyx Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Corporate Progress

Retrieved on: 
星期二, 二月 27, 2024
SAN, Ulcerative colitis, Quarter, Week, CDAI, Peripheral, Blood, Obesity, ALS, Research and development, Cryopyrin-associated periodic syndrome, NLRP3, Volunteering, Inflammation, Modulation, Multiple sclerosis, Rheumatology, Safety, UC, CAPS, CNS, Administration, Pharmacokinetics, Patient, TYK2, FCAS, G&A, Ulcer, Pharmaceutical industry

SAN DIEGO, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced financial results for the fourth quarter and full year ended December 31, 2023, and highlighted recent pipeline and business progress.

Key Points: 
  • Fourth Quarter and Full Year 2023 Financial Results:
    Cash Position: Cash, cash equivalents and marketable securities were $252.2 million as of December 31, 2023.
  • Research and Development (R&D) expenses: R&D expenses were $42.0 million for the fourth quarter of 2023, compared to $30.2 million for the fourth quarter of 2022.
  • General and Administrative (G&A) expenses: G&A expenses were $8.3 million for the fourth quarter of 2023, compared to $8.4 million for the fourth quarter of 2022.
  • Net loss: Net loss was $46.8 million for the fourth quarter of 2023, compared to $35.2 million for the fourth quarter of 2022.